Targeting C-Met/VEGF in Castration Resistant Prostate Cancer
作者： Petros D. Grivas , David C. Smith
DOI: 10.1007/978-1-4939-1176-9_19
关键词:
摘要: HGF/MET and VEGF/VEGFR pathways have emerged as rational therapeutic targets in castrate-resistant prostate cancer (CRPC). Preclinical studies support the role of inhibition these this challenging disease. Clinical trials using agents that inhibit either one but not both concurrently suggest modest activity with no overall survival benefit. Cabozantinib (Cabo) is a multi-targeted tyrosine kinase inhibitor against MET, VEGFR2, RET. A phase II randomized discontinuation trial patients metastatic CRPC showed significant improvement bone scans, turnover markers, pain response. However, Cabo was associated adverse events resulting dose reduction treatment discontinuation. Ongoing two III are expected to define CRPC. The development biomarkers predictive response will further refine targeted therapies management
springer.com
sci-hub.st 参考文章(81)
J. Morote, Judit Pallares, L.I. Armadans, F. Rojo, J. Iriarte, I. de Torres, Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histology and Histopathology. ,vol. 21, pp. 857- 865 ,(2006) , 10.14670/HH-21.857
Timothy L. Ratliff, Robin T. Vollmer, Peter A. Humphrey, Xiaopei Zhu, Mark L. Day, Paul E. Swanson, Reza Zarnegar, Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. American Journal of Pathology. ,vol. 147, pp. 386- 396 ,(1995)
TYROSINE 1356 IN THE CARBOXYL-TERMINAL TAIL OF THE HGF/SF RECEPTOR IS ESSENTIAL FOR THE TRANSDUCTION OF SIGNALS FOR CELL MOTILITY AND MORPHOGENESIS Journal of Biological Chemistry. ,vol. 269, pp. 29943- 29948 ,(1994) , 10.1016/S0021-9258(18)43972-5
William L. Dahut, Ravi A. Madan, Joyson J. Karakunnel, David Adelberg, James L. Gulley, Ismail B. Turkbey, Cindy H. Chau, Shawn D. Spencer, Marcia Mulquin, John Wright, Howard L. Parnes, Seth M. Steinberg, Peter L. Choyke, William D. Figg, Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer BJU International. ,vol. 111, pp. 1269- 1280 ,(2013) , 10.1111/J.1464-410X.2012.11667.X
Beatrice S. Knudsen, Magnus Edlund, Prostate cancer and the met hepatocyte growth factor receptor. Advances in Cancer Research. ,vol. 91, pp. 31- 67 ,(2004) , 10.1016/S0065-230X(04)91002-0
Gary E. Gallick, Hisanori Uehara, Sun Jin Kim, Matthew H. Herynk, Marjorie Johnson, Kristen Koterba, Reduced c-Met Expression by an Adenovirus Expressing a c-Met Ribozyme Inhibits Tumorigenic Growth and Lymph Node Metastases of PC3-LN4 Prostate Tumor Cells in an Orthotopic Nude Mouse Model Clinical Cancer Research. ,vol. 9, pp. 5161- 5170 ,(2003)
Akinobu Maeda, Koh-ichi Nakashiro, Shingo Hara, Toyokazu Sasaki, Yoshihiro Miwa, Nozomu Tanji, Masayoshi Yokoyama, Hiroyuki Hamakawa, Ryoichi Oyasu, Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochemical and Biophysical Research Communications. ,vol. 347, pp. 1158- 1165 ,(2006) , 10.1016/J.BBRC.2006.07.040
N FAUSTO, Hepatocyte growth factor receptor and the c-met oncogene Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802?804 Hepatology. ,vol. 14, pp. 738- 740 ,(1991) , 10.1016/0270-9139(91)90068-7
Emmanuel S Antonarakis, Michael A Carducci, Targeting angiogenesis for the treatment of prostate cancer Expert Opinion on Therapeutic Targets. ,vol. 16, pp. 365- 376 ,(2012) , 10.1517/14728222.2012.668887
Gautam Maulik, Amol Shrikhande, Takashi Kijima, Patrick C. Ma, Paul T. Morrison, Ravi Salgia, Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition Cytokine & Growth Factor Reviews. ,vol. 13, pp. 41- 59 ,(2002) , 10.1016/S1359-6101(01)00029-6